HDR prostate brachytherapy in conjunction with supplemental EBRT results in excellent biochemical relapse-free survival rates with a low incidence of severe late genitourinary or gastrointestinal toxicities. The use of short-term neoadjuvant androgen deprivation did not influence long-term biochemical tumor control in this cohort.
No takes yet. Share an insight, caveat, or question.
Kotecha et al. (2012) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: